Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pralatrexate
Drug ID BADD_D01814
Description Pralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009.
Indications and Usage Treatment of relapsed or refractory peripheral T-cell lymphoma.
Marketing Status approved; investigational
ATC Code L01BA05
DrugBank ID DB06813
KEGG ID D05589
MeSH ID C418863
PubChem ID 148121
TTD Drug ID D02LWU
NDC Product Code 72893-005; 47848-045; 53183-4020; 48818-001; 65219-550; 72893-003; 68554-0071; 65219-552; 65392-2510
UNII A8Q8I19Q20
Synonyms 10-propargyl-10-deazaaminopterin | pralatrexate
Chemical Information
Molecular Formula C23H23N7O5
CAS Registry Number 146464-95-1
SMILES C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.000168%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Vomiting07.01.07.003--
Malignant neoplasm progression16.16.01.0050.002462%Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.000112%Not Available
Adverse event08.06.01.010--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Disease progression08.01.03.0380.000895%
Tumour invasion16.16.01.0080.000112%Not Available
Chronic kidney disease20.01.03.017--
Bone marrow failure01.03.03.0050.000112%
Cytopenia01.03.03.0120.000224%Not Available
Oral disorder07.05.01.0050.000168%Not Available
Epstein-Barr virus associated lymphoproliferative disorder16.21.02.002; 11.05.10.001; 01.13.02.0020.000112%Not Available
Peripheral T-cell lymphoma unspecified01.11.06.001; 16.17.06.0010.000168%Not Available
Epstein-Barr virus associated lymphoma11.05.10.007; 01.15.01.003; 16.28.01.0030.000112%Not Available
Cutaneous T-cell lymphoma23.07.04.029; 16.17.03.002; 01.11.03.0020.000168%Not Available
The 3th Page    First    Pre   3    Total 3 Pages